Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer

Phase 2 Withdrawn Latin American Cooperative Oncology Group Janssen, LP · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, interventional study in racially self-identified black or ethnically self-identified hispanic and racially self-identified white or native American participants with metastatic castration-resistant prostate cancer whose tumors demonstrate molecular alterations compatible with homologous repair deficiency.

Timeline

Start: 2025-04-30
Primary completion: 2027-09-30
Completion: 2028-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abiraterone acetate	Small molecule	500 mg	—
Subject	Niraparib	Small molecule	100 mg	—
Background	Prednisone	Other / unclassified	5 mg	—

Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer

Summary

Timeline

Drugs

Indications